Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.64 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.64 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.63 |
| ▸ | AKT1 | P31749 | 1/20 | 0.61 |
| ▸ | CIT | O14578 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 2/20 | 0.55 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.53 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.53 |
| ▸ | PRKX | P51817 | 1/20 | 0.53 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.53 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802593 | 1.00 | ROCK2 (0.64) | ROCK2ROCK1AAK1GPR142AKT1 | |
| SCHEMBL10260826 | 1.00 | ROCK2 (0.64) | ROCK2ROCK1AAK1GPR142AKT1 | |
| Hydrochloric Acid SCHEMBL4525075 | 0.99 | ROCK2 (0.62) | ROCK2ROCK1AAK1GPR142AKT1 | |
| SCHEMBL9590958 | 0.92 | AKT1 (0.66) | ROCK2ROCK1AAK1GPR142AKT1 | |
| SCHEMBL4529357 | 0.88 | AAK1 (0.62) | ROCK2ROCK1AAK1GPR142CIT | |
| SCHEMBL2684698 | 0.87 | GPR142 (0.61) | ROCK2ROCK1AAK1GPR142AKT1 | |
| SCHEMBL2684701 | 0.87 | GPR142 (0.61) | ROCK2ROCK1AAK1GPR142AKT1 | |
| SCHEMBL27744399 | 0.87 | AAK1 (0.61) | ROCK2ROCK1AAK1GPR142AKT1 | |
| SCHEMBL4533616 | 0.87 | AAK1 (0.61) | ROCK2ROCK1AAK1GPR142AKT1 | |
| SCHEMBL4530047 | 0.87 | ROCK2 (0.69) | ROCK2ROCK1AAK1GPR142AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005756-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | NAVRATIL TOMAS (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299096-B2 | Method for treating pulmonary diseases using rho kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20100204210-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20090325958-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325958-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, RHOA, ROCK2 | ROCK2 3/4885ROCK1 1/4885AAK1 118/4885 |
| US-20100204210-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, RHOA, SERPINB1 | ROCK2 4/4885ROCK1 1/4885AAK1 91/4885 |
| US-20130005756-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, RHOA, ROCK2 | ROCK2 3/4885ROCK1 1/4885AAK1 118/4885 |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885AAK1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.